Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical reported Q3 2026 revenue of $3.05 billion, up 22% year over year, and non-GAAP EPS of $3.00, up 25%; procedures rose 15% and da Vinci system placements increased 28% to 546. Management narrowed full-year procedure-growth guidance to 14%–15% from 13.5%–15.5%, while projecting pricing actions will reduce da Vinci instrument-and-accessory revenue per procedure by approximately 3%–5% once fully implemented. GAAP results included a $450 million charge for a settlement subject to court approval; the company repurchased $2.94 billion of shares at an average $377 per share.

Analysis

The key signal is a widening gap between installed capacity and procedure growth: capital placements are accelerating, but U.S. procedure growth remains more modest. That is a forward bet on utilization, not yet proof of faster recurring-revenue conversion. If new systems are absorbed, the larger installed base compounds high-value consumables and service; if utilization disappoints, placement growth risks pulling demand forward and raises the chance of hospital capex digestion.

Pricing is the central second-order trade-off. Lower instrument costs may unlock benign procedures and ASC adoption, but the 3%–5% mix-constant I&A revenue-per-procedure headwind is more visible than the volume elasticity, which management cannot yet quantify. Watch procedure growth and I&A revenue per procedure together: volume acceleration that fails to offset pricing would pressure the recurring-revenue thesis. Tiered XiR pricing may also blunt modular-system competition from CMR Surgical and Stryker, though the ASC opportunity is early and placement data are lumpy.

Near term, strong placements and narrowed procedure guidance support sentiment, while the settlement is a quantified, one-time GAAP hit subject to court approval—not evidence that all future legal exposure is resolved. Over 1–3 months, China pricing implementation and U.S. procedure trends are the key checks. The Malaysia facility and telesurgery clearances are 2028 options, not current earnings drivers. Contrarian risk: investors may extrapolate system sales and new indications before utilization, evidence, reimbursement and adoption catch up. Conversely, if benign volumes respond to pricing, the market may underweight the longer-term installed-base flywheel.

Key Decisions for Investors

• Favor a measured long ISRG position on post-earnings weakness rather than chasing placements alone; scale only if procedure growth holds and I&A revenue per procedure stabilizes as pricing rolls out. No valuation or current price data are provided to support a numeric entry or target.
• Track quarterly U.S. procedure growth, system utilization, I&A revenue per procedure, and ASC placements. Treat volume growth that offsets price reductions as confirmation; recurring-revenue yield falling alongside slower utilization would falsify the adoption thesis and warrant reducing exposure.
• Monitor China price-policy execution and tender-driven placements separately from other regions; sustained deterioration in China capital placements or procedure growth would weaken the international growth case.
• Treat 2028 telesurgery and new-platform development as optionality, not a near-term catalyst. Reassess only as regulatory clearances, reimbursement, clinical evidence and commercial uptake become verifiable.